Chronic Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Chronic Hepatitis B (CHB) infection is characterized by the presence of Hepatitis B surface antigen (HBsAg) in the serum for at least six months. The markers HBeAg and HBV DNA, assessed using polymerase chain reaction (PCR) assays, serve as indicators of viral replication and infectivity, whereas HBsAg signifies the presence of hepatitis B viral infection. Severe complications associated with chronic infection encompass cirrhosis, liver failure, hepatocellular carcinoma, and mortality. In a minority of cases, HBV DNA can be detected in the serum without concurrent HBeAg presence. This phenomenon is attributed to the "pre-core" mutant, which impedes the production and release of the "e" antigen, despite ongoing HBV DNA replication and is associated with progressive liver disease. The risk of progressing to chronic hepatitis B following acute HBV infection varies with age; approximately 90% of infants progress to chronic conditions, while less than 5% of adults develop chronic illnesses. Transmission of HBV at a period of five years or younger can lead to significant long-term complications such as chronic hepatitis, cirrhosis, or hepatocellular carcinoma (HCC). Presently, two distinct therapeutic approaches have gained approval for treating CHB patients. These strategies include Interferon-alpha (IFN-α) or Pegylated-Interferon-alpha (Peg-IFN-α) and direct-acting antiviral medications, including nucleoside analogs such as lamivudine (LAM), telbivudine (LdT), and entecavir (ETV), as well as nucleotide analogs such as adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF).

 

Thelansis’s “Chronic Hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hepatitis B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Chronic Hepatitis B across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Hepatitis B Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chronic Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Chronic Hepatitis B, Chronic Hepatitis B market outlook, Chronic Hepatitis B competitive landscape, Chronic Hepatitis B market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)